Overview
- Editors:
-
-
John K. Buolamwini
-
University of Tennessee Health Science Center, Memphis
-
Alex A. Adjei
-
Mayo Clinic and Foundation, Rochester
Access this book
Other ways to access
Table of contents (26 protocols)
-
-
Introduction
-
-
- John K. Buolamwini, Haregewein Assefa
Pages 3-28
-
Kinase Inhibitor Discovery Protocols
-
-
- Judith S. Sebolt-Leopold, Keri Van Becelaere, Kenneth Hook, Roman Herrera
Pages 31-38
-
- Adrian M. Senderowicz, Tyler Lahusen
Pages 39-48
-
-
Angiogenesis and Metastasis Protocols
-
-
- Ronald S. Go, Whyte G. Owen
Pages 59-64
-
- Gregory I. Frost, Per Borgström
Pages 65-78
-
- Elvira Olaso, Fernando Vidal-Vanaclocha
Pages 79-86
-
- Martin Sattler, Elizabeth Quackenbush, Ravi Salgia
Pages 87-105
-
- Lorea Mendoza, Fernando Vidal-Vanaclocha
Pages 107-115
-
- Jianing Zhang, Michiko N. Fukuda
Pages 117-121
-
- Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan, Amy Ostendorf, Stephen D. Gillies, Paul M. Sondel
Pages 123-131
-
Immunohistochemical Assays in the Clinical Setting
-
Front Matter
Pages 133-133
-
- Shazli N. Malik, Roble G. Bedolla, Manuel Hidalgo, Michael G. Brattain, Jeffrey I. Kreisberg
Pages 135-140
-
-
Protein Chaperoning/Degradation Protocols
-
Front Matter
Pages 147-147
-
- Wynne Aherne, Alison Maloney, Chris Prodromou, Martin G. Rowlands, Anthea Hardcastle, Katherine Boxall et al.
Pages 149-161
About this book
We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.
Editors and Affiliations
-
University of Tennessee Health Science Center, Memphis
John K. Buolamwini
-
Mayo Clinic and Foundation, Rochester
Alex A. Adjei